New pill combo could slow stomach cancer progression
NCT ID NCT07552402
First seen May 12, 2026 · Last updated May 21, 2026 · Updated 1 time
Summary
This study tests whether taking two oral drugs—paclitaxel solution and fruquintinib—can help people with advanced stomach or gastroesophageal junction cancer live longer without their disease getting worse. It is for patients whose cancer did not respond to or caused side effects from first-line treatment. About 150 adults will be randomly assigned to receive either the new drug combo or the doctor's choice of standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.